Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1754 - A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-&bgr;) receptor I kinase inhibitor (galunisertib) in combination with anti–PD-1 (nivolumab) in advanced refractory solid tumours


09 Oct 2016


Poster display


Susan Guba


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


S.C. Guba1, S. Mukhopadhyay2, D. Desaiah1, V.A.M. Andre3

Author affiliations

  • 1 Oncology, Eli Lilly and Company, 46285 - Indianapolis/US
  • 2 Oncology, Bristol-Myers Squibb, 08543 - Princeton/US
  • 3 European Early Phase Stats, Erl Wood ELCL, WINDLESHAM/GB


Abstract 1754


TGF-β signaling plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance. Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-β receptor I kinase that specifically down-regulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway. Programmed Cell Death-1 (PD-1) is expressed on activated T cells and can act to dampen the immune response. Tumor cells overexpress PD-1 ligand (PD-L1) and inhibit the local immune response. Nivolumab blocks the binding of PD-L1 to its PD-1 receptor, allowing the activated T cells to identify and attack cancer cells. Thus, blockade of both TGF-β and PD-1 could be expected to reverse the immune escape and to potentially provide immune restoration to improve immune response and induce tumor regression.

Trial design

This study (NCT02423343) is a phase 1b/2 open-label study that will be conducted in 2 parts. The phase 1b is an open-label, dose-escalation assessment of the safety and tolerability of galunisertib administered in escalating doses over 4 cohorts ending with 150 mg BID in combination with nivolumab 3 mg/kg IV every 2 weeks in patients with advanced refractory solid tumors. The phase 2 will be disease restricted and includes 3 expansion cohorts of patients with non-small cell lung cancer (n = 25), hepatocellular carcinoma (n = 25), or glioblastoma (n = 25). Patients in the 3 cohorts will be assigned to treatment concurrently, and enrollment will be complete when all cohorts have reached the prespecified enrollment target. Enrollment of patients in phase 1b began on 09 October 2015; as of 27April2016, seven patients entered the study; one withdrew for a non-DLT reason, and one patient remains on treatment every 2 weeks.

Clinical trial identification


Legal entity responsible for the study

Eli Lilly and Company


Eli Lilly and Company


S.C. Guba, D. Desaiah, V.A.M. Andre: Author is an employee of Eli Lilly and Company and holds company stock. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings